-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*For medical professionals only
Scientific treatment + good attitude is a good prescription
for advanced lung cancer.
Lung cancer is the malignant tumor with the highest incidence and mortality in China, which seriously threatens people's life safety and quality of life, especially advanced lung cancer, which accounts for about 70% of the newly treated non-small cell lung cancer (NSCLC), and the 5-year survival rate is less than 5% [1].
So that people "talk about cancer discoloration", which has a serious impact on the treatment efficacy and long-term survival benefits, timely adjustment of mentality, optimism for the treatment of lung cancer patients is particularly important
.
The protagonist of today's story, Ms.
Li (pseudonym here), is a patient with advanced lung cancer, let's listen to Ms.
Li's story: be an "obedient" patient!
Listen to your son
In 2019, I suddenly began to cough and cough up phlegm, but I didn't take it seriously, I didn't go to the hospital, it dragged on for four months, it became more and more serious, and it has had a great impact
on my life.
After I told my son, he took me to the hospital, did a series of tests, and did not tell me what the disease was, but said that he would have a minor operation
.
I listened to my son and finished the operation; After the operation, I said that I wanted to get infusion in the hospital, so I went for the infusion
.
But after the infusion, I felt very uncomfortable, nausea, vomiting, and even difficulty swallowing, how can the general infusion react so much?
Later, under my questioning, my son told me that it turned out to be lung cancer.
.
.
It's just a cough, how can it become lung cancer?
Listen to the doctor
At first, I was very desperate and could not accept the news at all, but my son and daughter-in-law persuaded me that medical technology is now very advanced, and encouraged me to actively treat it
.
It just so happened that my grandson was born at this time, and after seeing my grandson, I have no regrets, let me treat me
.
During the treatment, the doctor also often gave me encouragement, informed me of the situation in time, everything was relatively smooth, and I saw that the patients in the same ward were optimistic and positive, chemotherapy, taking medicine, chatting, walking, life continued as usual, as if lung cancer is not so terrible
.
I actively cooperated with the doctor's treatment, chatted with patients, and my son came to accompany me
from time to time.
Although I still had some discomfort and lost my hair, the doctor's professional guidance and everyone's encouragement slowly made me build my confidence
.
My mentality is getting better and better, no longer cranky, how to treat, how to deal with side effects, I listen to the doctor, in addition to this I just need to relax and live
well.
Listen to yourself
After the chemotherapy, I was discharged from the hospital and went home, and the doctor told me that after I went back, I only needed to continue taking an oral medicine called anlotinib, and then come back regularly for check-ups
.
So far, I have been taking medicine for more than 3 years, during which I have been reviewing, and the doctor said that my review results are all good, and the tumor is shrinking
further.
Now there are fewer adverse reactions, only occasional diarrhea, and the doctor has also prescribed drugs to treat diarrhea, which I can fully tolerate
.
And the hair I lost because of chemotherapy also grew up, and when I went out to play mahjong, people around me said that I didn't look like a sick person
.
I am now in a good state of mind, no longer pay too much attention to diseases, my attitude towards life is more optimistic, and my son and daughter-in-law are also very supportive of me
.
I think that a good attitude is very helpful for treatment, and I hope that patients with the same disease can also face it optimistically, actively treat it, and return to normal life as soon as possible like me
.
Expert comment:
Professor Zhu Xueqiang
I am very pleased
that this patient is currently in good condition overall and his quality of life has improved significantly.
Patients with malignant tumors may have only one chance of optimal treatment, and the pathological type of this patient is not very clear, so the choice of treatment regimen needs to be more cautious
.
The treatment of tumors emphasizes individualization, analysis according to the specific situation of the patient, and requires a positive attitude and the courage
to try at all times.
This patient was able to benefit from small molecule multi-target anti-angiogenesis inhibitor therapy for more than 3 years, which may be related to his unique pathological type, and now it seems that the choice of oral anlotinib is a scientific attempt, and I also believe more and more that individualized treatment is an effective treatment strategy
to help patients with advanced lung cancer benefit.
Of course, the patient's good attitude and compliance also play a very important role
in the treatment process.
It is hoped that this patient can continue to obtain longer-term benefits in the treatment of anlotinib, and also hope that there will be more and more good drugs to bring more gospel
to lung cancer patients.
The treatment of malignant tumor patients is becoming more and more "standardized" and "full-course", building trust with patients and carrying out standardized diagnosis and treatment of lung cancer throughout the process management will help enhance the awareness of clinicians of standardized diagnosis and treatment and disease management, so as to find the best solution to maximize the clinical benefits of patients, benefit more cancer patients, and help achieve the goal of "Healthy China 2030" as soon as possible
.
Wong Wai
Ms.
Li's diagnosis process was relatively tortuous, and she was initially diagnosed with small cell lung cancer (SCLC)
locally.
After coming to our hospital, we invited American pathologists to conduct remote pathology consultation, as well as discussions with many pathologists in our hospital, and finally diagnosed non-small cell lung cancer (NSCLC).
However, the specific type is not very clear, tends to low-grade adenocarcinoma, and the genetic test results are also wild type, and there is no corresponding targeted drug for treatment
.
The family did not inform the patient of the actual condition at first, and it may be that due to the long time taken by the early diagnosis, Ms.
Li was in advanced NSCLC when she came to our hospital to be diagnosed, and the patient felt very desperate
when she learned of the condition.
However, although the patient and the family had a very difficult stage, they were still more cooperative in treatment, and during this period, the patient's grandson was born, which gave the patient very positive psychological comfort
.
Later, the patient slowly built up confidence in the good treatment effect and everyone's encouragement, actively treated, optimistic life, obtained significant survival benefits, and returned to normal life
.
.
A clinical study from Shanghai Second Military Medical University confirmed that telling patients the truth is beneficial to treatment
.
The researchers recruited a total of 29,825 lung cancer patients and followed up every six months to register and track
the diagnosis, pathological type, stage, age, and whether they knew the disease.
The median survival time for patients with known disease was 18.
33 months and that of patients who did not know was 8.
77 months (P<0.
001)</b10>
Ms.
Li had chemotherapy for 6 cycles, during which nausea, vomiting, and severe hair loss occurred, but Ms.
Li persevered
.
At the end of chemotherapy, the patient's condition was generally stable and progressed
slightly.
Considering that the pathological type of the patient is not very clear, we suggest the direct use of the small molecule multi-target tyrosine kinase inhibitor anlotinib, which has been approved for both SCLC and NSCLC and may achieve good efficacy
.
After communication, the patient and family expressed understanding and actively cooperated with the treatment
.
After the application of anlotinib, the patient's condition was quickly and significantly controlled, the efficacy achieved partial remission (PR), and the adverse reactions were also mild, mainly manifested as oral mucositis and diarrhea
.
Because the patient has understood the condition, we have also informed us in advance of possible adverse reactions, the patient has corresponding psychological expectations, and if there are adverse reactions, we are also informed in time for symptomatic treatment, and the overall adverse reactions of the patient are tolerable
.
After the end of chemotherapy, the patient regrows thick hair, and his mentality is getting better and better, returning to normal life, entertainment, optimism, and active treatment
.
At present, the patient is still taking the drug on time, regular review, and the latest review results show that the patient's tumor is still shrinking further, and the survival benefit has been more than 3 years
.
Ms.
Li's mentality is gradually adjusted during the treatment process, and we have established trust, good attitude and compliance have played a very positive role in Ms.
Li's entire treatment, laying a solid foundation for the improvement of treatment efficacy and quality of life, and Ms.
Li will still follow up regularly
.
It is hoped that Ms.
Li's optimistic and positive attitude towards cancer treatment can encourage more patients who struggle with cancer to cooperate with treatment and improve survival benefits
.
Huang Hui interview: Expert
profile
: Professor Zhu Xueqiang
Member of the Standing Committee of the Radiotherapy Committee of Sichuan Medical Association
Director of Western Sichuan Radiotherapy Association
Member of the esophageal cancer special committee of Sichuan Anti-Cancer Association
Member of Gastric Cancer Committee of Sichuan Cancer Society
Member of the Targeted and Immunotherapy Committee of Sichuan Oncology Society
Visiting scholar at James Cancer Center, Ohio State University
Visiting scholar at the Cancer Center of Inha University Hospital, South Korea
Expert profilesHuang Hui
Attending physician of Sichuan Provincial People's Hospital
Research interests: thoracic tumors
Participated in and was responsible for a number of clinical research projects in the direction of esophageal cancer, and presided over a Wu Jieping Medical Foundation
Member of Sichuan Association for the Promotion of International Exchanges
Member of Gene and Cell Therapy Committee of Sichuan Cancer Society
Member of the Standing Committee of Radiotherapy and Immunotherapy of Chengdu Anti-Cancer Association
Member of the Lung Cancer Diagnosis and Treatment Integration Committee of Chengdu Anti-Cancer Association
Published as first author in journals such as Oncogene, Cell & Death, Biomedicine & Pharmacothrapy, among others
References:
[1] The Expert Committee of Vascular Targeted Therapy of the Chinese Society of Clinical Oncology, the Expert Committee of Non-small Cell Lung Cancer of the Chinese Society of Clinical Oncology, and the Expert Group of Anti-Angiogenic Therapy for Non-small Cell Lung Cancer of the Chinese Society of Clinical Oncology.
Chinese expert consensus on antiangiogenic drugs for advanced non-small cell lung cancer(2020 edition)[J].
Chinese Journal of Oncology,2020,42(12):1063-1077.
)
[2] Su T, He C, Li X, et al.
Association between early informed diagnosis and survival time in patients with lung cancer.
Psychooncology.
2020 May; 29(5):878-885.
